

EMA/MB/458302/2021
Management Board meeting of 7 October 2021

Decision of the Management Board

Amending budget No. 01, amending appropriations in budget 2021

THE MANAGEMENT BOARD,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council, and in particular Article 67(11) thereof,

Having regard to the Financial Regulation applying to the Agency, and in particular Articles 26, 33 and 34 thereof,

Having regard to the proposal of the Executive Director representing the Agency,

Having regard to the revised forecast of fee revenue related to scientific applications expected in 2021,

Having regard to the plan for implementation of activities related to the extended mandate of the Agency

Having regard to the revised forecasts of expenditure related to staff, infrastructure and operations, and operational activities,

Whereas any amendments to the budget, including the establishment plan, shall be subject to an amending budget adopted by the same procedure as the initial budget.

HAS DECIDED

Article 1

The Agency's general budget (fund source C1) for 2021 shall be amended as detailed in Annex I below.

Article 2

The Executive Director shall implement this decision.

Amsterdam, 7 October 2021

[Signature on file]

Christa Wirthumer-Hoche
Chair of the Management Board

Annex 1 to EMA/MB/458302/2021

Item	Description	Outturn as per year-end accounts	Appropriation as per adopted budget	Amending budget No. 1	Appropriation adopted and amending budget
		2020	2021	2021	2021
REVENUE					
Title 1	Revenue from services rendered				
1000R	Fees collected (Regulation (EU) 297/95)	€ 291,631,351	€ 302,127,000	€ 8,735,000	€ 310,862,000
1001R	Fees collected (Regulation (EU) 658/2014)	€ 25,257,467	€ 28,282,000	-€ 213,000	€ 28,069,000
Title 2	European Union and EEA contributions				
2000R	European Union and EEA contribution	€ 33,703,605	€ 41,070,000	-€ 17,811,000	€ 23,259,000
Title 5	Revenue from administrative activities and ancillary services				
5200R	Revenue from administrative activities and ancillary services	€ 0	€ 62,000	-€ 62,000	€ 0
Title 9	Miscellaneous revenue				
9000R	Miscellaneous revenue	€ 476,450	€ 0	€ 2,660,000	€ 2,660,000
Total revenue			-€ 6,691,000		
EXPENDITURE					
Title 1	Staff expenditure				
Chapter 11	Staff holding a post provided for in the list of posts				
1100	Basic salaries	€ 47,679,535	€ 52,583,000	€ 307,000	€ 52,890,000
1115	Seconded national experts and visiting experts	€ 5,877,480	€ 3,868,000	€ 386,000	€ 4,254,000
1190	Weightings and exchange rate	€ 8,521,708	€ 8,480,000	€ 1,639,000	€ 10,119,000
Chapter 16	External services				
1601	Interim services	€ 2,978,870	€ 6,703,000	€ 1,312,000	€ 8,015,000
1602	Administrative assistance from the European Union institutions	€ 553,351	€ 812,000	€ 650,000	€ 1,462,000
Title 2	Infrastructure & operating expenditure				
Chapter 21	Corporate information & communication technology				
2114	Maintenance & support of applications	€ 27,074,196	€ 26,180,000	€ 2,500,000	€ 28,680,000
Chapter 23	Current administrative expenditure				
2320	Financial charges	€ 200,451	€ 200,000	€ 200,000	€ 400,000
Title 3	Operational expenditure				
Chapter 30	Operational expenditure				
3010	Evaluation of medicinal products	€ 121,325,015	€ 120,663,000	€ 3,626,000	€ 124,289,000
3020	Translation centre, Luxembourg	€ 3,493,000	€ 3,549,000	€ 500,000	€ 4,049,000
Title IX	Provisional appropriations				
9000	Provisional appropriations	€ 0	€ 25,392,000	-€ 17,811,000	€ 7,581,000
Total expenditure			-€ 6,691,000		

Annex 2 to EMA/MB/458302/2021

Activity Based Budget (ABB)

Work programme activities	STAFF (FTEs)		Staff expenditure	Infrastructure, IT and project exp.	Meeting exp. (incl. overhead)	Evaluation Service (NCAs)	Other operational expenditure	Total expenditure	
			€'000	€'000	€'000	€'000	€'000	€'000	%
	Temporary Agent	Contract Agent & Seconded National Experts	Title 1	Title 2 & Budget Item 3105	Budget item 3000 & 3003	Article 301	Articles 302, 303		
Evaluation activities for human medicines	279	99	59,240	27,810	5,832	133,639	10,100	236,620	63%
Pre-authorisation activities	62	27	14,286	4,509	3,300	24,680	47	46,822	12%
Initial evaluation activities	68	15	13,346	2,693	579	16,551	1,163	34,333	9%
Post-authorisation activities	67	22	13,526	10,596	110	79,029	5,586	108,848	29%
Referrals	12	3	2,157	458	70	-	288	2,973	1%
Pharmacovigilance activities	42	23	9,636	3,212	1,010	13,379	3,004	30,242	8%
Other specialized areas and activities	28	9	6,288	6,341	763	-	11	13,403	4%
Evaluation activities for veterinary medicines	30	15	6,606	11,426	1,154	4,074	604	23,863	7%
Pre-authorisation activities	2	0	262	73	154	215	1	705	0%
Initial evaluation activities	10	3	1,784	422	297	946	247	3,696	1%
Post-authorisation activities	9	3	1,589	766	73	2,913	214	5,555	2%
Arbitrations and Referrals	1	2	273	76	89	-	128	566	0%
Pharmacovigilance activities	1	2	433	310	199	-	13	955	0%
Other specialized areas and activities	8	4	2,266	9,779	341	-	-	12,385	3%
Public health activities and other areas	161	87	37,292	25,792	5,605	3,135	5,747	77,571	20%
Committee coordination	34	15	7,748	1,586	2,108	-	-	11,441	3%
Inspection and Compliance	23	21	5,940	1,658	497	3,135	299	11,529	3%
Partners and Stakeholders	22	10	5,168	1,285	2,551	-	833	9,838	3%
Transparency and access to documents	18	11	4,569	1,033	-	-	-	5,602	1%
Information	25	17	5,738	2,477	31	-	364	8,609	2%
International activities	9	6	2,552	454	98	-	-	3,104	1%
Information Management (incl. EU Telematics)	30	8	5,578	17,299	321	-	4,250	27,448	8%
Corporate Governance and Support activities	150	47	29,234	8,675	331	-	35	38,276	10%
Governance, quality management and internal audit	31	15	7,782	1,421	331	-	-	9,534	3%
Finance	29	10	5,321	2,015	-	-	35	7,371	2%
Information technology	36	9	7,378	1,609	-	-	-	8,986	2%
Human resources	46	13	7,501	3,044	-	-	-	10,544	3%
Infrastructure services	9	1	1,253	587	-	-	-	1,841	1%
Total	621	248	132,372	73,703	12,922	140,848	16,485	376,330	100%
							Brexit related expenditure	2,898	
							Budget 2021 following AB01	379,228	